CNBC's Angelica Peebles joins 'Squawk on the Street' with the latest news on drugmaker Pfizer.
Breakdown
- Pfizer's experimental sickle cell drug failed a phase 3 trial. 9s
- The drug was part of Pfizer's $5.5 billion acquisition of Global Blood Therapeutics. 22s
- Pfizer previously withdrew Oxbryta, the only approved medicine from the acquisition, due to safety concerns. 31s
- One more sickle cell drug from the acquisition remains in phase 3 development. 1m 4s
- Sickle cell disease has limited treatment options, and there is hope for more accessible therapies. 1m 13s